Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

UNITED THERAPEUTICS (UTHR) EBIT Margin: 2009-2025

Historic EBIT Margin for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to 48.59%.

  • UNITED THERAPEUTICS's EBIT Margin rose 278.00% to 48.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.63%, marking a year-over-year increase of 1621.00%. This contributed to the annual value of 47.86% for FY2024, which is 305.00% down from last year.
  • UNITED THERAPEUTICS's EBIT Margin amounted to 48.59% in Q3 2025, which was up 6.46% from 45.64% recorded in Q2 2025.
  • Over the past 5 years, UNITED THERAPEUTICS's EBIT Margin peaked at 62.35% during Q1 2022, and registered a low of -4,527.85% during Q4 2024.
  • In the last 3 years, UNITED THERAPEUTICS's EBIT Margin had a median value of 48.19% in 2025 and averaged -367.06%.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's EBIT Margin skyrocketed by 7,944bps in 2022, and later crashed by 457,016bps in 2024.
  • Over the past 5 years, UNITED THERAPEUTICS's EBIT Margin (Quarterly) stood at 40.90% in 2021, then crashed by 517bps to 35.73% in 2022, then skyrocketed by 659bps to 42.31% in 2023, then crashed by 457,016bps to -4,527.85% in 2024, then skyrocketed by 278bps to 48.59% in 2025.
  • Its last three reported values are 48.59% in Q3 2025, 45.64% for Q2 2025, and 48.19% during Q1 2025.